Funding for DX3 after the great results to date was expected and why not , the more we spend on different applications the more it's worth and a larger market cap. We are still worth much less than other ASX cancer stocks. Not for long imo .
.
3 assets now will be under development
PAT-DX1 for Brain Tumor Imaging and other Solid Tumors.
Preliminary research efforts by Imagion have demonstrated that the Patrys PAT-DX1 molecule can be conjugated to the MagSense® nanoparticles and provide bio-functionality for targeting certain cancer cell lines. Should this further collaborative work provide positive results, Imagion will have an exclusive option to a future license agreement, should it elect to commercialize the imaging agent.
"biopsy is the only definitive way they can be diagnosed and two thirds of primary brain tumors are benign. A non-invasive imaging method able to specifically identify malignant brain tumors and differentiate from benign disease would address a significant unmet medical need."
The combination of our two company’s technologies offers a range of exciting opportunities”, said Dr. James Campbell, Patrys’ CEO and Managing Director. “The potential for our deoxymab antibodies to home in on a range of different cancer types due to their affinity for DNA is one of the properties that makes them so unique and opens up a range of different clinical applications for their use. We are very excited to be further leveraging the cancer-targeting ability of deoxymabs by partnering with Imagion and its innovative MagSense® imaging technology to potentially develop new ways to visualise and diagnose cancer. This is the first of multiple potential applications of our deoxymab platform, and while our focus is on advancing our novel cancer therapeutics to the clinic we are actively engaged in business development efforts for the broader platform to leverage theunique attributes of deoxymabs.”
PAT-DX1
PAT-DX1 has been shown to cross the blood brain barrier, reduce tumour size, and increase survival in multiple animal models of brain cancer, other cancers, and cancer metastases.
PAT-DX1 is tumour-agnostic, meaning that it can target many different tumour types in the body, regardless of specific tumour antigens. Patrys believes that PAT-DX1 may have application across a wide range of cancers including gliomas, melanomas, prostate, breast, pancreatic,and ovarian cancers.
PAT-DX3
A preclinical study has demonstrated that Patrys’ full-sized deoxymab antibody, PAT-DX3, can be used as a targeting agent for antibody drug conjugates (ADC) to deliver anti-cancer drugs to tumours.
Patrys Chief Executive Officer and Managing Director, Dr. James Campbellsaid: “It is very exciting to report such positive data from our proof-of-concept study showing that Patrys’ deoxymabs may have potential as targeting agents for ADCs.
“While most ADCs are based on antibodies directed against cell surface antigens that are specific for a particular tumour, our deoxymabs are attracted to the DNA that is released from most cancers as a result of the high rates of cell death and cell turnover in tumours.
“This preclinical study has shown that the affinity our deoxymabs have for DNA is sufficient for them to target the delivery of cancer drugs to tumours where they can inhibit tumour growth and improve survival. This exciting finding may open up new opportunities for deoxymabs as a basis for developing new therapeutic ADC products.
PAB Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
(20min delay)